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To the Editor: Field clinicians working during the 
unprecedented Ebola virus disease (EVD) outbreak in 
West Africa, which began in December 2013, have been 
confronted with complex situations concerning mothers 
and breast-fed children in which one or both in a pair have 
tested positive for Ebola virus (EBOV) (1). More data, es-
pecially regarding virus shedding in breast milk, is critical 
to provide better care and guidance in future outbreaks. We 
report the case of a lactating EBOV-positive mother and 
her twin babies. The case is anonymously reported with the 
mother’s consent. The study met the Médecins Sans Fron-
tières Ethics Review Board and approved criteria for stud-
ies of routinely collected data.
In Guinea in 2015, a woman and her 4-month-old 
twins (baby 1 and 2) were registered as contacts after the 
woman’s mother tested positive for EBOV (postmortem 
diagnosis by reverse transcription PCR [RT-PCR]). The 
woman and her babies, who were exclusively breast-fed, 
were followed daily by contact tracers. When baby 1 be-
came febrile, the woman left her home to seek help from a 
traditional healer, bringing both twins with her. A few days 
later, baby 1 died and was buried without EBOV testing; 
according to the World Health Organization case definition, 
baby 1 was a probable EVD case-patient (2). 
Eleven days after baby 1 died, the woman became 
sick; 5 days later, she was admitted to an Ebola treatment 
center. At admission (day 0), she had headache, loss of ap-
petite, abdominal pain, joint pain, dysphagia, conjunctival 
injection, and myalgia but was afebrile. On day 1, a blood 
sample from the woman was positive for EBOV by RT-
PCR (Xpert Ebola Assay, GeneXpert Instrument Systems; 
Cepheid, Sunnyvale, CA, USA) with a cycle threshold (Ct) 
of 32.5. Baby 2 tested negative for EBOV on day 1 and 72 
hours later. Baby 2 was tested twice because he was con-
sidered at high risk for infection after being breast-fed for 6 
days while his mother was symptomatic (i.e., until day 1 of 
her hospital admission).
On day 1, the woman was given convalescent-phase 
plasma from EBOV survivors; the treatment was given ac-
cording to a compassionate-use protocol and was the stan-
dard process in this center at the time. On day 6, breast milk 
was sampled and tested positive for EBOV (Ct 21.6) (Table). 
The woman’s clinical course was favorable; she remained 
afebrile during hospitalization, but mild symptoms persisted 
until day 5. The first convalescent-phase test, done on day 14, 
showed Ct values of 40.5 and 27.5 for blood and breast milk, 
respectively. On day 21, a second breast milk sample tested 
positive (Ct 32.7). On day 24, the woman was given cabergo-
line (0.5 mg 2×/d for 2 days) to cease lactation, after which 
no more breast milk samples could be collected. On day 29 
after admission, she tested negative for EBOV in blood and 
urine and was reunited with baby 2. Serologic testing for 
baby 2 was done on day 23 and showed no sign of previous 
subclinical infection (ELISA, IgM, and IgG negative). 
Many questions in this case remain unanswered, but 
our findings show the potential infectivity of breast milk for 
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at least 26 days after EVD symptom onset and demonstrate 
a case in which a baby was not infected by breast milk from 
his EBOV-positive mother. However, it should be noted 
that the woman’s breast milk was never tested while she 
was breast-feeding baby 2.
The literature on EBOV in breast milk of EBOV-pos-
itive patients is extremely scarce (3). In a previous study 
from the 2000 Sudan EBOV outbreak in Gulu, Uganda, 
breast milk from a convalescent-phase patient was sampled 
15 days after symptom onset and tested positive for EBOV 
by RT-PCR and virus culture (4). Another study conducted 
in Guinea during the current outbreak, reported a mother–
baby pair in which EVD developed in the baby 14 days 
after symptom onset in the mother, but breast milk from the 
mother sampled 17 days after symptom onset was negative 
by EBOV RT-PCR (1). 
It is unclear whether infectious virus or defective 
particles are being secreted in breast milk. Ct values were 
consistently lower in breast milk than in blood when tested 
concomitantly, but in this case, breast milk samples were 
not collected until day 6. Our findings suggest that breast 
milk is infected by EBOV at a later stage of the disease than 
blood but then follows the expected replication kinetics ob-
served in venous blood.
Considering the high EVD death rate, until further evi-
dence is found, we recommend that EBOV-positive women 
stop breast-feeding immediately and that breast-feeding 
not be resumed until 2 negative RT-PCR tests of the breast 
milk have been confirmed. This suggestion is in line with 
the World Health Organization recommendation for testing 
semen in male EVD survivors (5). The public health risk 
for EBOV to remain in breast milk for at least 26 days after 
EVD symptom onset and for breast milk to possibly be in-
fectious after a patient has cleared the virus from the blood 
should also be acknowledged.
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Table. Overview of results from all Ebola virus RT-PCRs performed during hospitalization of breast-feeding mother of twin babies, 
Guinea, 2015* 
Day after admission Blood, Ct Breast milk, Ct Urine, Ct 
1 32.5, glycoprotein NT NT 
3 33.7, glycoprotein NT NT 
6 NT 21.6, nucleoprotein NT 
14 40.5, nucleoprotein 27.5, nucleoprotein NT 
18 41.0, glycoprotein NT NT  
21 40.3, nucleoprotein 32.7, nucleoprotein NT  
25 39.3, nucleoprotein NT NT 
29 Negative, glycoprotein and 
nucleoprotein 
NT Negative, glycoprotein and 
nucleoprotein 
*Testing performed by using the Xpert Ebola Assay (GeneXpert Instrument Systems, Cepheid, Sunnyvale, CA, USA). The lowest of the reported 
glycoprotein and nucleoprotein values are reported. Ct values <20 are highly positive, whereas Ct values >35 are weakly positive. Ct, cycle threshold; NT, 
not tested. 
 
